Study Hipra HH-4: Promising vaccine against SARS-CoV-2 in immunosuppressed adults

The Hipra HH-4 study is a multicenter investigation aimed at evaluating the immunogenicity and safety of an RBD fusion vaccine (PHH-IV) against SARS-COV-2. This study specifically focused on adults with immunosuppressive conditions who were already vaccinated against COVID-19.

The CRO ScienHub Research Support coordinated the monitoring tasks among the three recruiting centers, and the CTU implemented the study at our center, collaborating closely and determinedly with the respective research teams.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop